New solutions include customized reagents that scale from bench to clinical trials, industrialized lentiviral vector ...

The right approaches are demonstrating that it is possible to breach the defensively designed blood-brain barrier despite its ...

Good morning, everyone, and thank you for joining Naturgy's First Quarter 2026 Results Presentation. This is Abel Arbat speaking from the Capital Markets team at Naturgy. Next to me sits the Global ...

Globally, RSV is responsible for an immense health and economic burden, causing an estimated 33 million new ALRI cases and ...

Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology ...